Epitopea Partners with Merck to Discover Cryptigen Tumor-Specific Antigens
Shots:
- Epitopea & Merck have entered into license & research collaboration agreement to discover Cryptigen tumor-specific antigens (TSAs) in an undisclosed solid tumor
- As per the deal, Epitopea will receive an undisclosed upfront & ~$300M in milestones per product in exchange for Merck receiving exclusive development & commercialization rights to the TSA products identified via Epitopea’s CryptoMap platform
- Cryptigen TSAs are shared, non-mutated antigens that are aberrantly expressed & derived from genomic regions previously acknowledged as non-coding or junk DNA
Ref: Epitopea | Image: Epitopea & Merck
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
